Swissmedic approves the extension of the booster dose (booster dose) to all persons aged 16 and over

Bern, 11/23/2021 – After reviewing the data submitted in the last few days, Swissmedic is adjusting the information for healthcare professionals on the Covid-19 mRNA vaccine from Pfizer / BioNTech (Comirnaty®). This paves the way for a wider use of the booster vaccination. People at particular risk can continue to receive a booster vaccination from the age of 12.

Swissmedic has checked the documents submitted by the authorization holder last week for the third dose and is adapting the product information. From now on, people over the age of 16 can be given a booster dose. As provided for in the Swissmedic decision of October 26, 2021, the booster is still possible for people at particularly high risk from the age of 12. In any case, the condition is that the second dose has been taken at least six months ago.

Third vaccination with the same dose

Swissmedic made this decision based, among other things, on a study with 10,000 participants aged 16-87. The interim results of this study did not reveal any new risk aspects for the vaccine. The basic immunization with Comirnaty takes place with two doses of 0.3 ml at an interval of three weeks. The now approved booster vaccination at least six months later can continue to protect against Covid 19 disease.

Use and safety of the Covid-19 vaccines

Based on the amendment of the drug information by Swissmedic, the Federal Commission for Vaccination Issues (EKIF) is now specifying the vaccination recommendations. Swissmedic continues to closely monitor the benefits and risks of the vaccine to prevent coronavirus disease in Switzerland and internationally.

See also  ▷ POL-E: Mülheim an der Ruhr: Cunning con artists pull out all the stops to ...

Address for queries

Media office

+41 58 462 02 76
[email protected]


Swissmedic, Swiss Agency for Therapeutic Products